A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations

Hirohito Yamaguchi* and Ghina M. Taouk

Cancer Research Center, College of Health and Life Sciences, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha, Qatar

Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) are the downstream effectors of the Hippo signaling pathway that play a crucial role in various aspects of cancer progression including metastasis. Metastasis is the multistep process of disseminating cancer cells in a body and responsible for the majority of cancer-related death. Emerging evidence has shown that cancer cells reprogram their metabolism to gain proliferation, invasion, migration, and anti-apoptotic abilities and adapt to various environment during metastasis. Moreover, it has increasingly been recognized that YAP/TAZ regulates cellular metabolism that is associated with the phenotypic changes, and recent studies suggest that the YAP/TAZ-mediated metabolic alterations contribute to metastasis. In this review, we will introduce the latest knowledge of YAP/TAZ regulation and function in cancer metastasis and metabolism, and discuss possible links between the YAP/TAZ-mediated metabolic reprogramming and metastasis.

Keywords: YAP, TAZ, cancer, metabolism, metastasis

INTRODUCTION

Metastasis is the spread of cancer cells from primary tumors to distinct organs and a major cause of cancer-related death. Therefore, targeting metastasis is expected to be an effective therapeutic strategy to improve the survival of cancer patients. Metastasis is a complex process including various distinct steps, and cancer cells need to gain diverse abilities in each step that are regulated by a variety of cellular signaling pathways (1). Thus, the understanding of regulatory mechanisms of metastasis is particularly crucial for targeting it.

During tumor development, cancer cells are exposed to dynamic changes of tumor microenvironment such as availability of nutrient and oxygen. Hence, cancer cells need to adapt their metabolism to these changes to develop tumors (2). Emerging evidence has suggested that metabolic reprogramming also plays a significant role in metastasis, during which cancer cells are exposed to different environment from primary tumors to distant metastatic sites (3).

Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) are the transcriptional co-regulators and downstream effectors of the Hippo signaling pathway (4). Numerous studies using mouse models have demonstrated that YAP/TAZ promotes tumor development, progression, and metastasis (4). At cellular level, YAP/TAZ regulates cell cycles, migration, invasion, anchorage-independent growth, epithelial-mesenchymal transition (EMT), and stemness. Because all these functions of YAP/TAZ are crucial for various steps of metastasis, YAP/TAZ serves as a central regulator of metastasis. Besides, it has gradually been recognized that YAP/TAZ regulates cellular metabolic reprogramming to adapt the various tumor microenvironment (5).
Based on the fact that YAP/TAZ has the ability to regulate both metastasis and metabolism, it is expected that YAP/TAZ functions as a central hub for metastasis by regulating both metabolic adaptation and phenotypic changes required for metastasis. Thus, in this review, we will introduce the latest knowledge of YAP/TAZ regulation and function in cancer metastasis and metabolism, and discuss possible links between the YAP/TAZ-mediated metabolic reprogramming and metastasis.

REGULATION OF YAP/TAZ

YAP/TAZ is the downstream effector of the Hippo signaling pathway, which is an evolutionally conserved kinase cascade (Figure 1) (6, 7). The key regulators of the Hippo pathway include two kinases mammalian sterile 20-like kinase 1 and 2 (MST1/2) and large tumor suppressor kinase 1 and 2 (LATS1/2) and their regulatory subunits SAV1 and MOB1, respectively (Figure 1) (6). MST1/2 forms a complex with SAV1, which phosphorylates and activates the downstream LATS1/2-MOB1 complex (6). Activated LATS1/2 phosphorylates YAP/TAZ at multiple serine/threonine residues. Upon phosphorylation, YAP/TAZ interacts with 14-3-3, resulting in its cytoplasmic sequestration (8). Alternatively, phosphorylated YAP/TAZ is ubiquitinated by E3 ligase β-TrCP and undergoes proteasome-dependent degradation (9, 10). Thus, MST1/2 and LATS1/2 are the negative regulators of YAP/TAZ. Unphosphorylated YAP/TAZ moves to the nucleus, where YAP/TAZ interacts with (TEA domain) TEAD family transcription factors and functions as a transcription co-activator (11, 12). Major YAP/TAZ target genes include molecules that are related to cell growth, proliferation, and migration such as CTGF, CYR61, MYC, AXI, BIRC5, and CCND1 (13, 14).

Various extracellular stimuli regulate YAP/TAZ through the Hippo signaling pathway-dependent and independent mechanisms. In particular, YAP/TAZ plays a central role in cellular mechanotransduction, which is a molecular process to convert various extracellular mechanical forces to cellular responses (15). Namely, mechanical cues from surrounding extracellular matrix (ECM) and cells are converted to biochemical signals to control gene expression and protein functions, resulting in cell proliferation, survival, differentiation, and migration (16). YAP/TAZ nuclear localization and activity are regulated by various mechanical cues, and activated YAP/TAZ is required for biological function induced by mechanical cues (17–20). Increased polymerized actin (F-actin) induced by mechanical cues contributes to YAP/TAZ activation through Hippo-dependent and independent mechanism, although the detail mechanism is still uncertain (21). Moreover, various G-protein-coupled receptors (GPCR) induces F-actin through RHOA activation, resulting in LATS1/2 inactivation and subsequent YAP/TAZ activation (22).

Besides, several upstream regulators of MST/LATS have been identified. Tao kinase (TAOK) phosphorylates and activates MST1 and LATS1/2 (23), and several mitogen-activated protein kinase kinase kinase kinase (MAP4K) family members directly phosphorylate and activate LATS1/2 (24, 25). A recent study has also shown that STK25 phosphorylates LATS1/2 and contribute to the activation of LATS1/2 in response to contact inhibition and cell detachment (26). In addition, tumor suppressor Neurofibromin 2 (NF2) is a critical activator of LATS1/2 (27). Therefore, these molecules ultimately inactivate YAP/TAZ. In contrast, NUAK2 phosphorylates LATS1 and inhibits it, thereby activating YAP/TAZ (28), while MAP/microtubule affinity-regulating kinase 4 (MARK4) can phosphorylate MST2 and SAV1, resulting in the disruption of MST2/SAV1/LATS1 complex and subsequent YAP/TAZ activation (29).

In addition to LATS-mediated phosphorylation, YAP/TAZ is regulated by a variety of molecules. Angiomotin (AMOT) and protein tyrosine phosphatase non-receptor type 14 (PTPN14) directly bind to YAP to sequester YAP in the plasma membrane (30, 31). Besides, it has been shown that YAP/TAZ is found in the β-catenin destruction complex and it is released from the complex upon Wnt ligand and translocates to the nucleus (32). Moreover, multiple kinases directly phosphorylate YAP/TAZ at the various sites that are different from LATS-mediated phosphorylation sites, and activate or inactivate it. For example, in response to cellular energy stress, AMP-activated protein kinase (AMPK) phosphorylates YAP and inactivates it (33, 34). CDK1 phosphorylates YAP during the G2–M phase of the cell cycle, and the CDK1-mediated YAP phosphorylation has been implicated to be linked to mitotic defects (35). In response to osmotic stress, NLK phosphorylates YAP and inhibits the interaction between YAP and 14-3-3, thereby enhancing its nuclear localization (36). Aurora A also interacts with and phosphorylates YAP in the nucleus, and contributes to YAP transcriptional activity (37). Furthermore, PYK2 is implicated to phosphorylate TAZ at its tyrosine residues and regulate its protein stability (38). Several receptor tyrosine kinases (RTKs) including FGFR, RET, and MERTK are also shown to phosphorylate YAP/TAZ and activate it (39).

A major function of YAP/TAZ is transcriptional regulation through DNA binding protein TEAD family proteins (40, 41). Several regulatory mechanisms for the YAP/TAZ-TEAD complex have been identified. VGLL4 inhibits YAP by competing with YAP for its TEAD-binding (42). TIAM1 interacts with YAP/TAZ and impairs the YAP/TAZ-TEAD interaction (43). Moreover, osmotic stress induces the interaction between TEAD and p38 MAP kinase, resulting in TEAD translocation to the cytoplasm and YAP/TAZ inactivation (44). In addition to these factors, YAP/TAZ has been reported to interact with other transcription regulators such as RUNX2 and AP-1, cooperate to regulate the expression of target genes (45). Therefore, YAP/TAZ is regulated by a variety of stress and stimuli through multiple mechanisms (Figure 1).

THE ROLE OF YAP/TAZ IN CANCER PROGRESSION

YAP/TAZ functions as an oncogenic transcription factor in majority of solid tumors. Numerous studies have demonstrated that high expression and/or nuclear localization of YAP/TAZ
in cancer cells are correlated with poor clinical outcomes in many cancer types such as lung, colorectal, breast, liver, gastric, pancreatic, prostate, endometrial, esophageal, bladder, and ovarian cancer (4, 46, 47). Moreover, it has been shown that the signatures of YAP/TAZ regulated gene expression are correlated with poor prognosis of lung and breast cancers (48, 49). Moreover, gene inactivation by mutations or deletions in multiple upstream regulators of the Hippo pathway, such as LATS1/2, PTPN14, and NF2 has been identified in several cancers including mesothelioma, skin basal cell carcinoma, and bladder and colon cancer (50–52).

In addition to retrospective analysis of clinical samples, numerous animal studies have also verified the function of YAP/TAZ as a bona-fide oncogenic factor. For example, conditional knockout of MST1/2 in liver or liver-specific YAP overexpression induces spontaneous liver cancer (53–55). Ectopic expression of YAP promotes tumor formation and progression in the genetically engineered mouse (GEM) model of lung cancer (56). Moreover, genetic inactivation of YAP reduces or suppresses tumor formation in various GEM models of lung, breast, colon, and pancreatic cancer (56–59).

At the cellular level, YAP/TAZ is involved in diverse functions required for tumor progression. For example, YAP/TAZ promotes cell proliferation by upregulating many genes involved in cell cycle control such as CCND1, CDK1, CDC25, and MCMs (40, 60, 61). YAP/TAZ also promotes anchorage-independent growth in various cancer cells (37, 62, 63). To establish tumors, cancer cells need to escape from immune surveillance. Recently, it has been demonstrated that YAP/TAZ is involved in immune evasion as well as the resistance to immune checkpoint inhibitors (64). For instance, YAP/TAZ has been shown to upregulate chemokine CXCL5 and CCL2, resulting in the recruitment of immune suppressive myeloid-derived suppressor cells (MDSC) and M2 macrophages, respectively (65, 66). YAP/TAZ also upregulates PD-L1 in cancer cells, which is a critical regulator for the immune checkpoints (67, 68).
Furthermore, some studies have indicated that YAP/TAZ is essential for the maintenance of cancer stem cells. For example, TAZ is required for maintenance of breast cancer stem cells (49), while in osteosarcoma, YAP functions downstream of SOX2 to maintain cancer stem cells (69). In basal like breast cancer cells, serum response factor (SRF) interacts with YAP and induces IL-6 expression, which promotes stemness of basal like breast cancer cells (70). In esophageal cancer cells, YAP induces SOX9, which is engaged in cancer stem cell properties (71, 72).

During cancer development, cancer cells require high energy and a large amount of building blocks to maintain their growth and proliferation. However, because of limited oxygen and nutrients in tumor microenvironment, cancer cells are exposed to various metabolic stress and need to adapt their metabolism to it (73). Recent studies have shown that YAP/TAZ is not only regulated by diverse metabolic signals, but also serves as a key regulator of various metabolic pathways (5).

Therefore, YAP/TAZ obviously plays an essential role in cancer progression (Figure 2). In addition to the functions that were discussed earlier, YAP/TAZ regulates various cellular functions that are essential for metastasis, such as cell migration, invasion, survival, and EMT. We will discuss these functions in detail in the next section.

**METASTASIS REGULATION BY YAP/TAZ**

It has been recognized that metastasis occurs through multiple steps known as the metastatic cascade. First, cancer cells gain the ability of migration and invasion, and these cells are dissociated from primary tumors to enter blood and lymphatic vessels. Then, the cells circulates in the blood stream, and some surviving cells extravasates at distant tissues and organs to form secondary tumors (1, 74).

Multiple retrospective analyses of clinical samples have shown that the upregulation or nuclear localization of YAP/TAZ is correlated with metastasis in a variety of cancer such as breast, colorectal, gastric, lung, liver, and pancreatic cancer (75–80). Similarly, the downregulation of upstream negative regulators of the Hippo pathway is also associated with metastasis in the various cancer (81–84).

Moreover, a number of in vivo studies have demonstrated the role of YAP/TAZ in metastasis. Overexpression or activation of YAP/TAZ promotes the ability of cancer cells to metastasize in xenograft mouse models of several cancer types (85–87). In contrast, inactivation of YAP/TAZ suppresses metastasis in several mouse models (87, 88).

At the cellular level, YAP/TAZ has been demonstrated to regulate multiple essential steps of the metastatic cascade (Figure 2). Cell migration and invasion abilities are crucial for cancer cell metastasis, and many studies have shown that overexpression and activation of YAP/TAZ promotes cell migration and invasion (85, 89–92), while the inhibition of YAP/TAZ reduces the migration and invasion abilities of cancer cells (91–93). Mechanistically, YAP/TAZ has been shown to control cell motility by limiting cytoskeletal and focal adhesion maturation (94). Moreover, YAP/TAZ promotes cell migration and invasion through the upregulation of various downstream targets, such as Axl, Cyr61, and receptor for hyaluronan-mediated motility (RHAMM) (89, 95, 96).

EMT is the process that epithelial cells lose their characteristics of cell polarity and cell-cell adhesion and gain mesenchymal cell properties, and associated with cell motility (97, 98). Because the initial step of metastasis is the detachment of cells from a tumor mass, EMT is considered to be the first event for metastasis (97, 99). Numerous studies have shown that YAP/TAZ is a key regulator of EMT. Overexpression of YAP/TAZ induce EMT (11, 12, 93, 100, 101), while the inhibition of YAP/TAZ reverses EMT (93, 102, 103). Mechanistically, several YAP/TAZ targets such as Axl, Cyr61, and CTGF have been shown to have the ability to induce EMT and stemness (104–106). Moreover, YAP has been shown to interact with Smad2/3/4 and regulate the mRNA expression of EMT-inducing transcription factors, Snail, Twist1, and Slug (107). EMT-inducing transcription factor ZEB1 also interacts with YAP and enhances its transcription activity (108).

During metastasis, cancer cells get into blood vessels and circulate in a body. For cancer cells to metastasize, they need to evolve a mechanism, which helps them to survive during their circulation in blood vessels. Anoikis is the type of apoptotic cell death that is induced by cell detachment, and gaining an ability of resistance toward anoikis is critical for cancer cells to metastasize (109). It has been shown that YAP/TAZ is able to inhibit anoikis (84). Interestingly, platelets interacts with cancer cells, in which YAP is activated through RHOA-MYPT1-PP1-mediated YAP dephosphorylation (110). The platelets-mediated YAP activation contributes to resistance to anoikis and metastasis (110). Moreover, it has been shown that fluid shared stress activates YAP/TAZ, suggesting that YAP/TAZ is activated during circulation and the activated YAP/TAZ may contribute to cancer cell survival during metastasis (111, 112).

**THE ROLE OF YAP/TAZ IN GLUCOSE METABOLISM**

Glucose is an essential source of energy and building blocks for cells. It is metabolized through glycolysis, TCA cycle, and oxidative phosphorylation (OXPHOS) to produce ATP. In the presence of oxygen, normal cells primarily generate ATP through oxidative phosphorylation and exhibit reduced glucose consumption. However, cancer cells uptake high levels of glucose and convert it to lactate via glycolysis regardless of the presence of oxygen (aerobic glycolysis). The enhanced glycolysis, pentose phosphate, and hexosamine biosynthetic pathways support the energy and building blocks required for high replication of cancer cells (113).

It has been demonstrated that YAP/TAZ is inactivated under the low glucose condition or by the inhibition of glycolysis while it is activated in response to high levels of glucose (33, 34, 114, 115). Several distinct mechanisms of glucose-mediated YAP/TAZ activation have been identified (Figure 3).

AMPK is a key cellular metabolic sensor that is activated by a high AMP to ATP ratio (116). As described earlier section, studies have shown that AMPK directly phosphorylates...
YAP and inhibits its transcriptional activity (33, 34). Also, these studies have indicated that LATS is also activated by glucose deprivation and contributes to YAP inactivation independently of AMPK, although the underlying mechanism is uncertain (33, 34). Another study has revealed that AMPK phosphorylates angiomotin-like 1 (AMOTL1), resulting in the stabilization of AMOTL1, which contributes to LATS-mediated YAP phosphorylation and inactivation (114).

O-GlcNAcylation is a posttranslational modification of proteins that is catalyzed by O-GlcNAc transferase (OGT) (117, 118). Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is a donor sugar of O-GlcNAcylation and transferred to serine/threonine residues of myriad target proteins by OGT (117, 118). UDP-GlcNAc is synthesized from glucose through the hexosamine biosynthetic pathway, which links to cellular O-GlcNAcylation levels (118). Moreover, it has been shown that aberrant protein O-GlcNAcylation is associated with metabolic reprogramming in cancer (119). It has been reported that YAP is also O-GlcNAcylated in response to high levels of glucose (120, 121). One study has shown that YAP is O-GlcNAcylated at Serine 109 (S109) by OGT under high glucose, and S109-O-GlcNAcylation of YAP prevents YAP-LATS interaction, thereby activating YAP (121). In contrast, another study has revealed that O-GlcNAcylation of YAP at threonine 214 (T214), which is also induced by high levels of glucose, enhances its stability by inhibiting the β-TrCP-YAP interaction. Besides, T214 O-GlcNAcylation of YAP is associated with YAP tumorigenic activity (120). Moreover, it has been reported that AMOT is also O-GlcNAcylated, and AMOT expression and O-GlcNAcylation is enhanced by high levels of glucose (122). Interestingly, AMOT enhances YAP nuclear localization and transcriptional activity under the high glucose condition while AMOT inhibits them in normal levels of glucose, suggesting that AMOT O-GlcNAcylation is another mechanism of YAP/TAZ regulation by high level of glucose (122).

In addition to the above mentioned mechanism, phosphofructokinase (PFK1), which is one of the enzymes regulating glycolysis, has been implicated to regulate YAP/TAZ activity (115). Inhibition of glycolysis with 2-deoxy-glucose (2DG) reduces TEAD-YAP complex formation, thereby reducing YAP-mediated transcription. Activated PFK1 interacts with TEAD and form a complex with TEAD and YAP, resulting in stabilization of the YAP-TEAD complex and YAP activation (115).

Methylglyoxal (MG) is a byproduct of glycolysis that induces protein glycation and formation of advanced glycation end products (AGEs). A study has revealed that high MG-adducts and nuclear YAP are correlated in breast cancer, and MG induces YAP activation in breast cancer cells (123). Mechanistically, MG induces HSP90 glycation, which impairs its chaperon activity on LATS1, resulting in destabilization of LATS1 protein and subsequent YAP activation (123).

Pyruvate kinase M2 (PKM2) is a splice isoform of pyruvate kinase that plays an critical role in aerobic glycolysis in cancer.
YAP/TAZ regulation by glucose metabolism and YAP/TAZ-targets for glucose metabolism. YAP/TAZ is inhibited by AMPK directly or indirectly through AMOTL1-mediated LATS activation. LATS is inhibited by PKM2 or Methylglyoxal, resulting in YAP/TAZ activation. YAP activation is also induced by direct O-GlcNAcylation or indirect O-GlcNAcylation of AMOT. In the nucleus, PKM2, PFK1, or Myc interacts with the YAP/TAZ-TEAD complex and enhances its transcriptional activity toward to the genes involved in glucose metabolism. YAP/TAZ induces lncRNA BCAR4, which interacts with GLI2 and induces PFKFB3 transcription.

(124). It has been reported that tyrosine 105-phosphorylated PKM2, which is induced by several tyrosine kinases, reduces LATS1 protein stability and downregulates it, thereby activating YAP (125). Furthermore, another report has shown that PKM2 directly interacts with YAP and enhances YAP transcriptional activity (126).

Because YAP/TAZ promotes cell growth and proliferation that require high nutrients, it is rational that YAP/TAZ is activated by high cellular glucose and inhibited under a limited energy source. However, in this context, it is also reasonable that YAP/TAZ controls glycolysis to support cell growth and proliferation. Indeed, emerging evidence has shown that YAP/TAZ regulates glycolysis by upregulating the key enzymes for the pathway as well as glucose transporters (Figure 3).

It has been demonstrated that knockdown of YAP/TAZ downregulates various genes involved in glycolysis including GLUT3, HK1, HK2, PFKFB4, PFKP, GAPDH, PGK1, PGAM1, LDHA, PDHA1, and PDHB, resulting in the downregulation of glycolysis and upregulation of mitochondrial oxidative phosphorylation in renal cell carcinoma cells (127). In cancer cells from a KRAS mutant pancreatic cancer GEM, deletion of YAP downregulates the expression of HK2, ALDOA, GPADH, PGK1, PGAM1, and LDHA genes (128). Interestingly, YAP cooperates with other transcription regulators to control many genes related to glycolysis. For example, YAP interacts with HIF1α and regulates the transcription of various genes involved in aerobic glycolysis such as GLUT1, HK2, ALDOA, LDHA, and PKM2 (129, 130). The YAP-TEAD complex interacts with p65 and upregulates the transcription of HK2 (131). YAP associates with c-Myc and regulates PGAM1 mRNA expression (132). Besides, YAP directly regulates transcription of GLUT3, and PKM2 enhances GLUT3 expression by interacting with YAP (126). In addition to direct transcriptional regulation, YAP also indirectly upregulates HK2 and PFKFB3 expression and glycolysis via the lncRNA BCAR4-GLI2 axis (133).

**THE ROLE OF YAP/TAZ IN LIPID METABOLISM**

Another key metabolic reprogramming that is critical for cancer progression is adaptation of lipid metabolism (134). Cancer
cells require high levels of lipid to maintain their growth and proliferation, and exhibit elevated *de novo* synthesis or uptake of lipid compared to normal cells (134). A growing body of evidence has shown that YAP/TAZ is not only activated by the dysregulated lipid metabolism pathways but also plays a role in the adaptation of lipid metabolism in cancer (Figure 4).

*De novo* fatty acid synthesis is activated in cancer cells for the maintenance of membrane synthesis and generation of signaling molecules (135). Stearoyl-CoA-desaturase I (SCD1) is an enzyme that synthesizes monounsaturated fatty acids, and a study has shown that the inhibition of SCD1 downregulates YAP/TAZ expression, nuclear localization, and activity, suggesting that monounsaturated fatty acids are crucial for YAP function (136). The study has also indicated that SCD1 activates YAP/TAZ through the inhibition of the β-catenin destruction complex, which is likely induced by the upregulation of lipid modified Wnt proteins (136). Palmitic acid is a common saturated fatty acid in organisms. It has been reported that palmitic acid inhibits YAP by upregulating MST1, thereby inhibiting endothelial cell proliferation, migration, and angiogenesis (137). Mechanistically, palmitic acid induces mitochondrial damage, which results in releasing mitochondrial DNA (mtDNA) to the cytoplasm. The cytoplasmic mtDNA further activates cGAS–STING–IRF3 signaling, which subsequently induces MST1 transcription (137). In contrast to endothelial cells, free fatty acids (FFA) including palmitic acid activate YAP via F-actin rearrangement in pancreatic β-cells (138). Notably, CTGF induced by YAP plays a role in protection of β-cells from FFA-induced apoptosis (138).

Protein S-palmitoylation is the post-translational modification by which palmitate is attached to cysteine residues of proteins, leading to protein association with membrane, localization changes, and/or functional alterations. Several studies have demonstrated that TEAD is palmitoylated and TEAD palmitoylation is critical for YAP/TAZ function (139–141). Although TEAD palmitoylation does not affect TEAD localization or membrane binding, it is important for the TEAD-YAP/TAZ interaction or proper TEAD folding and stability (139–141). Interestingly, TEAD is autopalmitoylated under physiological conditions (139). Moreover, a recent study has shown that TEAD palmitoylation is regulated by cell density (140). Mechanistically, high cell density induces NF2-dependent downregulation of fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), which are the crucial enzymes for *de novo* biosynthesis of palmitate (140). Moreover, high cell density upregulates the expression of depalmitoylases including APT2 and ABHD17A, which may contribute to TEAD depalmitoylation and subsequent TEAD downregulation (140). Therefore, these results suggest that TEAD palmitoylation serves as the potential regulatory mechanism of YAP/TAZ in response to cellular fatty acid metabolism.
The mevalonate pathway is another lipid metabolic pathway to synthesize sterols and isoprenoids from acetyl-CoA. The intermediate products of the mevalonate pathway including farnesyl pyrophosphate and geranylgeranyl pyrophosphate serve as substrates for protein farnesylation and geranylgeranylation, which plays a significant role in protein localization and function (142). Several studies have revealed that YAP/TAZ is regulated by the mevalonate pathway (96, 143, 144). These studies have further identified the underlying mechanism, in which the activation of YAP/TAZ by the mevalonate pathway is mediated by geranylgeranylation of RHOA and subsequent RHOA activation (96, 143, 144).

Lipophagy is the autophagic degradation process of lipid droplets, and a recent study has shown that oxidized low-density lipoprotein (oxLDL) lipophagy is associated with YAP activation and hepatocellular carcinoma (HCC) progression (145). In brief, endoplasmic reticulum-residential protein, Nogo-B is upregulated by the CD36-mediated oxLDL uptake, and Nogo-B interacts with ATG5 to promote oxLDL lipophagy, resulting in YAP activation likely through the upregulation of lysophosphatidic acid (LPA), which is a ligand of GPCR (145).

In addition to YAP/TAZ regulation by lipid metabolism, recent studies have shown that YAP/TAZ regulates lipid metabolism. The sterol regulatory element-binding proteins (SREBPs) are transcription factors that control the expression of enzymes involved in fatty acid and cholesterol biosynthesis (146). It has been reported that YAP interacts with the nuclear forms of SREBP1 and SREBP2 and enhances their transcriptional activities toward fatty acids synthase (FAS) and 30-hydroxymethyl glutaryl coenzyme A reductase (HMGCR) (147). Also, the study has shown that the activation of LAT51 or inhibition of YAP reduced hepatic steatosis and hyperlipidaemia in diet-induced diabetic mice (147).

Fatty acid oxidation (FAO) is the metabolic pathway that degrade fatty acid to supply ATP and acetyl-CoA and the activity of FAO is promoted in various cancer types (148). Recently, it has been proved that knocking-down YAP reduces FAO while YAP overexpression activates it (149). In addition, the study has indicated that YAP-mediated metabolic shift to FAO is critical for lymph nodes metastasis in a melanoma mouse model (149).

THE ROLE OF YAP/TAZ IN AMINO ACID METABOLISM

In cancer, amino acid metabolism is also dysregulated. In particular, glutamine is a key amino acid involved in energy generation in TCA cycle, biosynthesis of essential molecules such as amino acid, nucleotide, and fatty acid, control of redox homeostasis, and regulation of cell signaling (150), enhanced glutamine uptake and glutaminolysis are essential for cancer cell proliferation and survival (151). YAP/TAZ has been shown to be involved in glutamine metabolism by upregulating various genes involved in it (Figure 5).

It has been reported that YAP/TAZ directly regulates the mRNA expression of glutamine transporters SLC38A1 and SLC7A5 in HCC and these transporters are required for YAP/TAZ-mediated proliferation of HCC cells (152). In a zebra fish model, YAP has been shown to reprogram glutamine metabolism and enhance liver tumor formation (153). Briefly, YAP upregulates glutamine synthetase (GLUL) expression and activity, resulting in the upregulation of glutamine and nucleotide biosynthesis (153). In pulmonary vascular cells, YAP/TAZ upregulates the expression of glutaminase 1 (GLS1) that is the enzyme regulating the first step in the glutaminolysis by generating glutamate from glutamine (154). Physiologically, endothelial cell proliferation is enhanced by vascular stiffness in pulmonary hypertension. YAP/TAZ is activated by mechanical cues from stiff ECM and results in endothelial cell proliferation by upregulating GLS1-mediated glutaminolysis (154). It has been revealed that EphA2 induces YAP/TAZ activation through RHOA activation, and activated YAP/TAZ promotes glutaminolysis through upregulation of GLS1 and SLC1A5 in HER2-positive breast cancer cells (155). This study has also showed that YAP/TAZ expression positively correlates with GLS1 and SLC1A5 expression in human breast cancer patient samples (155). Another study with breast cancer cell lines has indicated that YAP/TAZ reprograms metabolism of breast cancer cells to glutamine-dependent one by inducing glutamic-oxaloacetic transaminase (GOT1) and phosphoserine aminotransferase (PSAT1), which are the key enzymes to convert glutamate to α-ketoglutarate (α-KG) (156). Thus, these studies demonstrated that the YAP/TAZ-mediated glutamine metabolism plays a role in breast cancer progression. Moreover, a recent study has demonstrated that mechanical cues from stiff ECM activates glutamine metabolism through YAP/TAZ activation in both cancer cells and cancer-associated fibroblasts (CAFs) (157). YAP/TAZ upregulates not only GLS1 to increase glutamine metabolism, but also SLC1A3 to exchange amino acids between cancer cells and CAFs (157). Cancer cells utilize CAFs-derived aspartate for the nucleotide biosynthesis pathway to maintain their proliferation while CAFs use cancer cell-derived glutamate for the glutathione pathway to maintain redox homeostasis (157). Thus, the study has indicated that YAP/TAZ regulates tumor growth by coordinating non-essential amino acids flux within the tumor niche.

In addition to glutamine metabolism, YAP/TAZ is also associated with the regulation of other amino acids. For example, YAP/TAZ increases leucine uptake by upregulating high-affinity leucine transporter LAT1 (158). Moreover, a study has suggested that YAP/TAZ activates serine metabolism (159). Upregulation of amino acids leads to the activation of the mammalian target of rapamycin (mTOR) signaling pathway, which is crucial for cell growth and survival (160). Numerous studies have shown that YAP/TAZ is closely associated with mTOR signaling through amino acids. For example, YAP/TAZ upregulates mTOR activity through the upregulation of amino acid transporters (152, 158). In addition, YAP activates mTOR by downregulating PTEN (161). Alternatively, the mTOR pathway has been shown to control YAP/TAZ activity through various mechanisms such as inhibition of autophagy, MST1, and AMOTL2, suggesting that cellular amino acids can regulate YAP/TAZ via activation of mTOR (162–164).
FIGURE 5 | YAP/TAZ-targets for amino acid metabolism. YAP/TAZ regulates amino acid metabolism by upregulating various factors involved in amino acid transportation such as SLC1A3, SLC1A5, SCL7A5, and SLC38A1 as well as glutamine metabolism by upregulating GLS1, GLUL, GOT1, and PSAT1. Moreover, upregulation of amino acids induces the activation of mTOR, which also activates YAP/TAZ through various mechanisms.

POTENTIAL LINK BETWEEN METABOLIC REGULATION AND METASTASIS BY YAP AND TAZ

Growing evidence has indicated that metabolic reprogramming plays a critical role in metastasis (165). As mentioned in the earlier section, metastasis consists of multiple steps, in which cancer cells need to reprogram cellular metabolism to adapt to the drastic changes of environment. In addition, it has been revealed that metabolic reprogramming is associated with the phenotypic changes of cancer cells to gain specific ability required for metastasis (3).

Glycolysis is upregulated in metastatic cancer cells compared to non-metastatic ones (166), and the inhibition of glycolysis attenuates metastasis (167). EMT is a critical step for cancer cells to initiate metastasis and associated with cell migration and invasion ability, and glycolysis has been shown to be closely associated with EMT (168, 169). Induction of EMT in pancreatic ductal adenocarcinoma by tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) simultaneously reprograms glucose metabolism to enhance glycolysis (168). Moreover, EMT regulator Snail silences the expression of fructose-1,6-bisphosphatase (FBP1), which is a rate-limiting enzyme in gluconeogenesis (170). Loss of FBP1 enhances glycolysis and reduces OXPHOS, while, FBP1 inhibits tumorigenesis in vivo (170). Because YAP/TAZ is activated by high levels of glucose and can regulate both EMT and glycolysis, it may coordinate glycolysis and EMT to initiate metastasis.

Indeed, one report have demonstrated that YAP/TAZ-mediated glucose metabolism is vital for metastasis. In brief, glycolysis and glucose transporter Glut3 are upregulated in metastatic colorectal cancer cells, and Glut3 expression is correlated with poor survival in colorectal cancer patients (126). Interestingly, Glut3 overexpression increases YAP/TAZ expression while Glut3-induced cell migration, invasion, and tumor sphere formation activity are abrogated by YAP knockdown (126). Moreover, YAP induces Glut3 expression in colorectal cancer cells, and both YAP and Glut3 are required for high-fat/sucrose diet-mediated metastasis in a xenograft mouse model (126). Thus, YAP/TAZ and Glut3 regulates each other to control glycolysis and metastasis in colorectal cancer (Figure 6). In addition to glycolysis, OXHOS and activated mitochondria have been shown to play a role in metastasis (171, 172). Moreover, a study has revealed that specific metabolic
adaptations are required for breast cancer cells to metastasize to particular organs (173). Liver-metastatic cancer cells show enhanced glycolysis and reduced OXPHOS while bone- or brain-metastatic cancer cells display enhanced OXPHOS (173). So far, it is uncertain whether YAP/TAZ is involved in organ-specific metastasis. However, considering YAP/TAZ promotes glycolysis, it may contribute to organ-specific metastasis.

Several reports have indicated that the lipid metabolic pathways are also associated with metastasis. For example, in ovarian cancer, fatty acid incorporation via CD36 is required for cell migration and invasion (174). In contrast, in A549 non-small lung cancer cells, lipogenesis plays a negative role in TGF-β-induced EMT and metastasis (175). Therefore, the role of lipid metabolism may be context-dependent. In mevalonate-mediated YAP activation, YAP regulates RHAMM, which upregulates breast cancer invasion and migration activity (96). Moreover, the recent study using a melanoma mouse model has also showed that YAP-mediated FAO is critical for metastasis (149) (Figure 6). In this model, YAP activation enhances FAO and the enhanced FAO is required for lymph node metastasis. Additionally, YAP in the cancer cells is activated by bile acids, which is accumulated to high levels in the metastatic lymph nodes.

Glutamine metabolism has also been reported to be engaged in metastasis. For example, glutaminolytic enzyme glutamate dehydrogenase 1 (GDH1), has been shown to contribute to anoikis resistance and promote metastasis (176). Mechanistically, GDH1 enhances α-KG, which further regulates energy balance through the CamKK2-AMPK pathway after cell detachment (176). In colorectal cancer tissues, GLS1 expression is positively correlated with lymph node metastasis and advanced clinical stage (177). Moreover, GLS1 is induced by hypoxia via HIF1α in colorectal cancer cell lines, and knockdown of GLS1 reduces metastasis in a xenograft mouse model with colorectal cancer cells (177). So far, there is no direct evidence that YAP/TAZ-mediated glutaminolysis contributes to metastasis. However, because YAP/TAZ can regulate GLS1 expression and glutaminolysis, it is likely that YAP/TAZ-mediated glutaminolysis contributes to metastasis. Moreover, although the GDH1-CamKK2-AMPK pathway confers resistance to anoikis, YAP/TAZ is known to be negatively regulated by AMPK. Thus, the glutamine metabolism-mediated anti-apoptotic function may be context-dependent. Obviously further studies are necessary to address the role of YAP/TAZ in glutaminolysis-mediated metastasis.

**CONCLUDING REMARKS**

Recent advances in targeted therapy and immunotherapy have significantly improved survival rates of cancer patients. However, majority of metastatic cancer is still challenging to be cured. Therefore, it is important to understand the pathways that are involved in metastasis and identify the potential druggable targets. As we described here, YAP/TAZ is activated by high nutrient conditions, and regulates multiple aspects of metastasis as well as cancer metabolism. Thus, YAP/TAZ would be a promising drug target for metastatic cancer. Although no effective clinical drugs targeting YAP/TAZ are available, multiple direct and indirect inhibitors for YAP/TAZ have been developed (178). Verteporfin, which is a photosensitizer for photodynamic therapy, has been known to inhibit YAP/TAZ activity by blocking YAP/TAZ-TEAD interaction and downregulating YAP/TAZ expression (179, 180). Indeed, multiple studies have demonstrated that verteporfin inhibits YAP/TAZ-dependent expression of the genes related to glycolysis and glutaminolysis and subsequent glycolysis and glutaminolysis in vitro and in vivo (126, 129, 153, 154, 157, 181). In addition to verteporfin, a peptide mimicking VGLL4 has also been shown to inhibit YAP/TEAD interaction and suppress tumor growth in vitro and in vivo (42). Moreover, several specific small molecule inhibitors for YAP-TEAD interaction have been developed (182–184). These inhibitors may have better therapeutic effects with less toxicity than verteporfin because of their specificity. As an alternative approach, YAP/TAZ upstream regulators, in particular protein kinases and other enzymes, would serve as potential drug targets for attenuating YAP/TAZ activity (178). However, YAP/TAZ is regulated by many upstream regulators and the regulatory mechanism may be dependent on cell context. Therefore, it is critical to identify key YAP/TAZ regulators in each tumor for targeting it. Moreover, the expression of YAP/TAZ-target genes would serve as a biomarker to monitor efficacy of therapy.
In recent years, numerous studies have demonstrated the role of YAP/TAZ in metabolism and metastasis. However, there are several critical questions that need to be answered to understand YAP/TAZ-mediated metabolism and metastasis.

Because YAP/TAZ is a multifunctional transcriptional regulator, it is expected to be involved in various steps of metastasis. However, it is still uncertain exactly how YAP/TAZ is regulated during metastasis. For example, EMT is considered as a first step for metastasis, but mesenchymal to epithelial transition (MET) also plays a role in it (185). Moreover, cancer cells reprogram their metabolism between high glycolysis and high OXPHOS during metastasis (3). Therefore, YAP/TAZ activity needs to be controlled strictly during metastasis. Cancer cells are exposed to diverse types of mechanical cues, and changes of nutrient and oxygen during metastasis, which may contribute to the regulation of YAP/TAZ and coordinate the cancer progression and metastasis. Indeed, some mechanical cues from ECM have been shown to promote EMT and metastasis as well as alter cellular metabolism (154, 157, 186, 187). In addition to LATS-mediated phosphorylation, YAP/TAZ is regulated by the interaction with other transcription factors and other proteins. Thus, during the metastasis and metabolic alterations, YAP/TAZ may change its binding partners so that it alters its function according to the need of microenvironment. In addition, various extracellular metabolites may affect YAP/TAZ binding partners and signaling, and contribute to metabolic adaptation and metastasis. Moreover, several reports have suggested that YAP also exhibits context-dependent tumor suppressor function (188, 189). The complicated metabolic regulation by YAP/TAZ may be associated with its tumor suppressor function. Thus, the understanding of the diverse role of YAP/TAZ in different cellular contexts may lead to a better therapeutic strategy to target metastatic cancer.

**AUTHOR CONTRIBUTIONS**

HY wrote the manuscript. GT made the figures and contributed to editing the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by a startup grant from Qatar Biomedical Research Institute, Qatar Foundation.

**ACKNOWLEDGMENTS**

We thank Qatar Biomedical Research Institute and Qatar Foundation for their support.

**REFERENCES**

1. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. *Cell*. (2011) 147:275–92. doi: 10.1016/j.cell.2011.09.024
2. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. *Cell Metab.* (2016) 23:27–47. doi: 10.1016/j.cmet.2015.12.006
3. Lehuede C, Dupuy F, Rabinovitch R, Jones RG, Siegel PM. Metabolic plasticity as a determinant of tumor growth and metastasis. *Cancer Res.* (2016) 76:5201–8. doi: 10.1158/0008-5472.CAN-16-0266
4. Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. *Cancer Cell*. (2016) 29:783–803. doi: 10.1016/j.ccell.2016.05.005
5. Koo JH, Guan KL. Interplay between YAP/TAZ and metabolism. *Cell Metab.* (2018) 28:196–206. doi: 10.1016/j.cmet.2018.07.010
6. Yu FX, Guan KL. The hippo pathway: regulators and regulations. *Genes Dev.* (2013) 27:355–71. doi: 10.1101/gad.210773.112
7. Zhao B, Tumaneng K, Guan KL. The hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. *Nat Cell Biol.* (2011) 13:877–83. doi: 10.1038/ncb2303
8. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev.* (2007) 21:2747–61. doi: 10.1101/gad.1602907
9. Liu CY, Zha ZY, Zhou X, Zhang H, Huang W, Zhao D, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF[beta]-TrCP E3 ligase. *J Biol Chem.* (2010) 285:37519–69. doi: 10.1074/jbc.M110.152942
10. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF[beta-TRCP]. *Genes Dev.* (2010) 24:72–85. doi: 10.1101/gad.1843810
11. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. *Genes Dev.* (2008) 22:1962–71. doi: 10.1101/gad.1664408
12. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. *J Biol Chem.* (2009) 284:13355–62. doi: 10.1074/jbc.M900843200
13. Mizuno T, Murakami H, Fuji M, Ishiguro F, Tanaka I, Kondo Y, et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. *Oncogene*. (2012) 31:5117–22. doi: 10.1038/onc.2012.5
14. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. *Semin Cell Dev Biol.* (2012) 23:785–93. doi: 10.1016/j.semcdb.2012.05.004
15. Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. *Nat Rev Mol Cell Biol.* (2017) 18:758–770. doi: 10.1038/nrm.2017.87
16. Jaaloul DE, Lammerding J. Mechanotransduction gone awry. *Nat Rev Mol Cell Biol.* (2009) 10:63–73. doi: 10.1038/nrm2597
17. Dupont S, Morsut L, Aragona M, Enzo E, Giuliani S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. *Nature*. (2011) 474:179–83. doi: 10.1038/nature10137
18. Aragona M, Panciera T, Manfrin A, Giuliani S, Michielin F, Elvassore N, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. *Cell*. (2013) 154:1047–59. doi: 10.1016/j.cell.2013.07.042
19. Meng Z, Qiu Y, Lin KC, Kumar A, Placone JK, Fang C, et al. RAP2 mediates mechanical responses of the Hippo pathway. *Nature*. (2018) 560:655–60. doi: 10.1038/s41586-018-0444-0
20. Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, Lucon Xiccato R, et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. *Nature*. (2018) 563:265–9. doi: 10.1038/s41586-018-0658-1
21. Dasgupta I, McCollum D. Control of cellular responses to mechanical cues through YAP/TAZ regulation. *J Biol Chem.* (2019) 294:17693–706. doi: 10.1074/jbc.REV119.007963
22. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling. *Cell*. (2012) 150:780–91. doi: 10.1016/j.cell.2012.06.037
23. Plouffe SW, Meng Z, Lin KC, Lin B, Hong AW, Chun JV, et al. Characterization of hippo pathway components by gene inactivation. Mol Cell. (2016) 64:993–1008. doi: 10.1016/j.molcel.2016.10.034

24. Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, Hong AW, et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the hippo pathway. Nat Commun. (2015) 6:8357. doi: 10.1038/ncomms9357

25. Zheng Y, Wang W, Liu B, Deng H, Uster E, Pan D. Identification of happyhour/MAP4K as alternative Hpo/Mst-like kinases in the hippo kinase cascade. Dev Cell. (2015) 34:642–55. doi: 10.1016/j.devcel.2015.08.014

26. Lim S, Hernandez N, Muidantio T, Mustaly HM, Mauricio IPM, Vittoria MA, et al. Identification of the kinase STK25 as an upstream activator of LATS signaling. Nat Commun. (2019) 10.15477. doi:10.14671-09979-w

27. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. (2013) 154:1342–55. doi: 10.1016/j.cell.2013.08.025

28. Gill MK, Christova T, Zhang YY, Gregorieff A, Zhang L, Narimatsu M, et al. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. Nat Commun. (2018) 9:5310. doi:10.1038/s41467-018-05939-2

29. Arash EH, Shiban A, Song S, Attisano L. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells. EMBO Rep. (2017) 18:420–36. doi:10.15252/embr.201642455

30. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, et al. Angiomotin is a novel hippo pathway component that inhibits YAP oncoprotein. Genes Dev. (2011) 25:51–63. doi:10.1101/gad.2009111

31. Michaloglou C, Lehmann W, Martin T, Deltaunay C, Hueber A, Barys L, et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS ONE. (2013) 8:e61916. doi:10.1371/journal.pone.0061916

32. Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. (2014) 158:157–70. doi: 10.1016/j.cell.2014.06.013

33. Mo JS, Meng Z, Kim YC, Park HW, Hansen CG, Kim S, et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the hippo pathway. Nat Cell Biol. (2015) 17:500–10. doi: 10.1038/nccell.3111

34. Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, et al. AMPK modulates hippo pathway activity to promote energy homeostasis. Nat Cell Biol. (2015) 17:490–9. doi: 10.1038/nccell.3113

35. Yang S, Zhang L, Liu M, Chong SJ, Chen Y, et al. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. (2013) 73:6722–33. doi:10.1158/0008-5472.CAN-13-2049

36. Hong AW, Meng Z, Yuan HC, Plouffe SW, Moon S, Kim W, et al. Osmotic stress-induced phosphorylation by NLK at Ser128 activates YAP. EMBO Rep. (2017) 18:72–86. doi:10.15252/embr.201642681

37. Chang SS, Yamaguchi H, Xia W, Lim SO, Khotyskaya Y, Wu y, et al. Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene. (2017) 36:1265–75. doi: 10.1038/onc.2016.292

38. Saadeldin MK, Shawer H, Mostafa A, Kassem NM, Amleh A, Siam R. New genetic variants of LATS1 detected in urinary bladder and colon cancer. Front Genet. (2014) 5:425. doi: 10.3389/fgene.2014.00425

39. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yapl oncogene. Cancer Cell. (2009) 16:425–38. doi: 10.1016/j.ccr.2009.09.026

40. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. (2010) 107:4347–42. doi: 10.1073/pnas.0911427107

41. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford S, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. (2007) 130:1120–33. doi: 10.1016/j.cell.2007.07.019

42. Zhang W, Gao Y, Li F, Tong X, Ren Y, Han X, et al. YAP promotes malignant progression of Lkb1-deficient lung adenosquamous carcinoma through downstream regulation of survivin. Cancer Res. (2015) 75:4450–7. doi: 10.1158/0008-5472.CAN-14-3396

43. Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnawa CA, et al. A temporal requirement for hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. (2014) 28:432–7. doi: 10.1101/gad.233676.113

44. Cai J, Maitra A, Anders RA, Taketo MM, Pan D. 8-Ar-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. Genes Dev. (2015) 29:1493–506. doi: 10.1101/gad.264515.115

45. Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. (2014) 7:ra42. doi: 10.1126/scisignal.2005049

46. Kapoor A, Yao W, Ying H, Hua S, Lieven A, Wang Q, et al. YAP1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. (2014) 158:185–97. doi: 10.1016/j.cell.2014.06.003

47. Kim W, Cho YS, Wang X, Park O, Ma X, Kim H, et al. Hippo signaling is intrinsically regulated during cell cycle progression by APC/C(Cdh1). Proc Natl Acad Sci USA. (2011) 108:4232–3. doi: 10.1073/pnas.101671

48. Yang N, Morrison CD, Liu P, Miecznikowski J, Bshara W, Han S, et al. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle. (2012) 11:2922–30. doi:10.4161/cc.21386

49. Matushita A, Sato T, Mukai S, Fujishita T, Mishiro-Sato E, Okuda M, et al. TAZ activation by hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation. Oncogene. (2019) 38:1966–78. doi:10.1038/s41388-018-0417-7
Yamaguchi and Taouk. YAP/TAZ-Mediated Metabolism and Metastasis

81. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki T, et al. Functional and clinical relevance of PD-L1 expression in lung adenocarcinoma. Mol Cancer. (2016) 15:190–9. doi: 10.1186/s12948-016-0339-3

78. Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, et al. Functional and clinical relevance of PD-L1 expression in lung adenocarcinoma. Mol Cancer. (2016) 15:190–9. doi: 10.1186/s12948-016-0339-3

82. Zhang J, Wang G, Chu SJ, Zhu JS, Zhang R, Lu WW, et al. Loss of large promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. (2005) 11:982–8. doi: 10.1158/1078-0432.CCR-04-1773

76. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. (2015) 34:681–90. doi: 10.1038/onc.2014.4.5

74. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Nat Rev Cancer. (2012) 12:337–47. doi: 10.1038/nrc3312

72. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, et al. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncotarget. (2015) 6:11892–902. doi: 10.18632/oncotarget.6961

70. Kim T, Yang SJ, Hwang D, Song J, Kim M, Kyum Kim S, et al. Lim: a basal-metastatic breast cancer-specific role for SRF-IL6 in YAP-induced breast cancer stem cell formation. Oncogene. (2019) 38:2042–55. doi: 10.1038/s41388-018-0476-9

68. Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, et al. YAP-induced PD-L1 expression drives immune evasion in BRAF-resistant melanoma. Cancer Immunol Res. (2018) 6:255–66. doi: 10.1158/2326-6066.CIR-17-0320

66. Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAP/TAZ and decreasing Cyr61 expression. Mol Cancer. (2012) 11:1380–5. doi: 10.1186/1556-0864-11-1380

64. Pan Z, Tian Y, Cao C, Niu G. The emerging role of YAP/TAZ in breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. Sci Signal. (2016) 9:ra12. doi: 10.1126/scisignal.aad3210

62. Zhou Z, Zhu JS, Gao CP, Li LP, Zhou C, Wang H, et al. siRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID mice. Oncol Lett. (2016) 11:2806–14. doi: 10.3892/ol.2016.4319

50. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition. Cancer Discov. (2016) 6:80–95. doi: 10.1158/2159-8290.CD-15-0224

48. Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, et al. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology. (2012) 82:205–12. doi: 10.1159/000336809

46. Pan Z, Tian Y, Cao C, Niu G. The emerging role of YAP/TAZ in tumor immunity. Mol Cancer Res. (2019) 17:1777–86. doi: 10.1158/1541-7786.MCR-19-0375

44. Guo Y, Pan Q, Zhang J, Xu X, Liu X, Wang Q, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. (2016) 6:80–95. doi: 10.1158/2159-8290.CD-15-0224

42. Janse van Rensburg HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, et al. The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1. Cancer Res. (2018) 78:1457–70. doi: 10.1158/0008-5472.CAN-17-3139

40. Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, et al. YAP-induced PD-L1 expression drives immune evasion in BRAF-resistant melanoma. Cancer Immunol Res. (2018) 6:255–66. doi: 10.1158/2326-6066.CIR-17-0320

48. Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, et al. MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology. (2012) 82:205–12. doi: 10.1159/000336809
its promoting role in cancer progression. Int J Oncol. (2017) 51:1055–66. doi: 10.3892/ijo.2017.4101

104. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. (2014) 33:1516–24. doi: 10.1038/onc.2013.57

105. Liu BC, Zhang JD, Zhang XL, Wu GQ, Li MX. Role of connective tissue growth factor (CTGF) module 4 in regulating epithelial mesenchymal transition (EMT) in HK-2 cells. Clin Chim Acta. (2006) 373:144–50. doi: 10.1016/j.cca.2006.05.029

106. Hou CH, Lin FL, Hou SM, Liu JF. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol Cancer. (2014) 13:236. doi: 10.1186/1476-4598-13-236

107. Zhang H, von Gise A, Liu Q, Hu T, Tian X, He L, et al. Yap1 is required for endothelial to mesenchymal transition of the atrioventricular cushion. J Biol Chem. (2014) 289:18681–92. doi: 10.1074/jbc.M114.554584

108. Lehmann W, Moshmann D, Kleemann J, Mock K, Meisinger C, Yamaguchi and Taouk Y. YAP/TAZ-Mediated Metabolism and Metastasis. Biochim Biophys Acta. (2019) 1833:3481–98. doi: 10.1016/j.bbadis.2013.06.026

109. Haeumerle M, Taylor ML, Gutschner T, Pradeep S, Cho MS, Sheng J, et al. Platelet-derived anoxia and promotes metastasis by activating YAP1 signaling. Nat Commun. (2017) 8:310. doi: 10.1038/s41467-017-00411-x

110. Lee HJ, Diaz ME, Price KM, Ozuna JA, Zhang S, Sevick-Muraca EM, et al. Fluid shear stress activates YAP1 to promote cancer cell motility. Nat Commun. (2017) 8:14122. doi: 10.1038/ncomms14122

111. Lee HJ, Ewere A, Diaz ME, Wenzel PL. TAZ responds to fluid shear stress to regulate the cell cycle. Cell Cycle. (2018) 17:147–33. doi: 10.1080/15384101.2017.1404209

112. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements for cell proliferation. Science. (2009) 324:1029–32. doi: 10.1126/science.1160089

113. DeRan M, Yang J, Chen R, Zhu S, Fan HY, Wang H, Lotze MT, Zeh HJ, et al. High mobility group protein B1 controls liver cancer initiation via yes-associated protein–dependent aerobic glycolysis. Hepatology. (2018) 67:1823–41. doi: 10.1002/hep.29663

114. Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene. (2017) 36:1435–43. doi: 10.1038/onc.2017.136

115. Zhang X, Han H, Liu GP, Ma YX, Pan RJ, Sang JI, et al. LncRNA wires up hipo and Hedgehog signaling to reprogramme glucose metabolism. EMBO J. (2017) 36:3325–33. doi: 10.15252/embb.201797609

116. Santos CR, Schulte A. Lipid metabolism in cancer. FEBS J. (2012) 279:2610–23. doi: 10.1111/j.1742-4658.2012.08644.x

117. Stingl J, de Vos M, Lotze MT, Zeh HJ, et al. The multifaceted roles of fatty acid synthase in cancer. Nat Rev Cancer. (2016) 16:732–49. doi: 10.1038/nrc.2016.89

118. Noto A, De Vitis C, Roscilli G, Ricci G, Catizone A, et al. Palmitic acid dysregulates the hippo-YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cystolic DNA sensor cGAS-STING-IRF3 signaling mechanism. J Biol Chem. (2017) 292:15002–15. doi: 10.1074/jbc.M117.800005

119. Deng Y, Matsui Y, Pan W, Lai ZC. Yap1 plays a protective role in suppressing free fatty acid-induced apoptosis and promoting beta-cell survival. Protein Cell. (2016) 7:562–72. doi: 10.1007/s13238-016-0258-5

120. Chan P, Han X, Zheng B, DeRan M, Yu J, Jia Y, et al. Autophagy inhibits expression of TEAD palmitoylation and activity. Proc Natl Acad Sci USA. (2019) 116:9877–82. doi: 10.1073/pnas.1819400116

121. Noland CL, Gierke S, Schnier PD, Murray J, Sandoval WN, Sagolla M, et al. Cunningham: palmitoylation of TEAD transcription factors is required for their stability and function in hipo pathway signaling. Structure. (2016) 24:179–86. doi: 10.1016/j.str.2015.11.005
YAP/TAZ-Mediated Metabolism and Metastasis

Frontiers in Oncology | www.frontiersin.org 15 June 2020 | Volume 10 | Article 928

Yamaguchi and Taouk
179. Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller JW, et al. The clinically used photosensitizer verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. (2014) 124:67–73. doi: 10.1016/j.exer.2014.04.011

180. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SI, Anders RA, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. (2012) 26:1300–5. doi: 10.1101/gad.192856.112

181. Du K, Hyun J, Premont RT, Choi SS, Michelotti GA, Swiderska-Syn M, et al. Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells. Gastroenterology. (2018) 154:1465–79.e13. doi: 10.1053/j.gastro.2017.12.022

182. Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. (2020) 37:104–22.e12. doi: 10.1016/j.ccell.2019.12.006

183. Bum-Erdene K, Zhou D, Gonzalez-Gutierrez G, Ghozayel MK, Si Y, Xu D, et al. Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEADYap protein-protein interaction. Cell Chem Biol. (2019) 26:378–89.e13. doi: 10.1016/j.chembiol.2018.11.010

184. Nouri K, Azad T, Ling M, van Rensburg HJJ, Pipchuk A, Shen H, et al. Identification of celastrol as a novel YAP-TEAD inhibitor for cancer therapy by high throughput screening with ultrasensitive YAP/TAZ-TEAD biosensors. Cancers. (2019) 11:1596. doi: 10.3390/cancers11101596

185. Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or permissive for metastasis? Mol Oncol. (2017) 11:755–69. doi: 10.1002/1878-0261.12083

186. Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat Cell Biol. (2015) 17:678–88. doi: 10.1038/ncb3157

187. Romani P, Brian I, Santinon G, Pocaterra A, Audano M, Pedretti S, et al. Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP. Nat Cell Biol. (2019) 21:338–47. doi: 10.1038/s41556-018-0270-5

188. Jho E. Dual role of YAP: oncoprotein and tumor suppressor. J Thorac Dis. (2018) 10(Suppl. 33):S3895–8. doi: 10.21037/jtd.2018.10.70

189. Lefort S, Tan S, Balani S, Rafn B, Pellacani D, Hirst M, et al. Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation. Oncogene. (2019) 39:1957–68. doi: 10.1038/s41388-019-1111-0

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yamaguchi and Taouk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.